The first molecular test was developed starting from the genetic alterations of the seven genes mostly involved in the papillary and follicular thyroid cancer, i.e., point mutations within BRAF, KRAS, HRAS and NRAS genes, and RET/PTC1, RET/PTC3 and PAX8/PPARγ rearrangements (4, 5). This evidence concerns the gene RET and thyroid gland follicular carcinoma.